DMIC
GMAB icon

Dixon Mitchell Investment Counsel’s Genmab GMAB Stock Holding History

Dixon Mitchell Investment Counsel’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
+416,000
New +$11.1M 0.37% 44

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dixon Mitchell Investment Counsel's GMAB Position: Q2 2026 in Review

Dixon Mitchell Investment Counsel opened a new position in Genmab (GMAB) in Q2 2026: 416,000 shares worth $11.4M. The stake represents 0.37% of the portfolio and ranks #44 among its holdings.

289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Dixon Mitchell Investment Counsel held 416,000 shares of Genmab worth $11.4M as of Q2 2026.
  • Genmab was a new Dixon Mitchell Investment Counsel position in Q2 2026.
  • Genmab made up 0.37% of Dixon Mitchell Investment Counsel's portfolio in Q2 2026, its #44 holding.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Dixon Mitchell Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.